此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)

2026年11月10日 更新者:Wake Forest University Health Sciences

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)

The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).

研究概览

详细说明

Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium. The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of atrial fibrillation or atrial flutter with rapid ventricular response. This study will use flat-dose intravenous metoprolol for rate control to minimize confounders. Additionally, this study will not require a resulted magnesium level prior to treatment in order to avoid delays in patient care.

研究类型

介入性

注册 (估计的)

196

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Illinois
      • Oak Lawn、Illinois、美国、60453
        • 招聘中
        • Advocate Christ Medical Center Emergency Department (ACMC ED)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age > 18 years or older
  • Able to provide informed consent
  • Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
  • Metoprolol as rate control agent
  • English speaking

Exclusion Criteria:

  • Hemodynamically unstable patients (SBP <90, MAP <65)
  • Impaired consciousness
  • Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
  • Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
  • Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
  • Acute myocardial infarction
  • Contraindications to magnesium sulfate (including myasthenia gravis)
  • Allergy or sensitivity to any study drugs
  • Previously enrolled in this trial during a different patient encounter
  • Withdrew from study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental Arm One, Magnesium Sulfate 2g followed by metoprolol 5 mg

Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity.

Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)

其他名称:
  • 硫酸镁 2 克/50 毫升 0.9% 氯化钠
实验性的:Experimental Arm Two, Magnesium Sulfate 4g followed by metoprolol

Study drug (Magnesium Sulfate 4 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity.

Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)

其他名称:
  • Magnesium Sulfate 4 gram/50ml 0.9% NaCl
安慰剂比较:Control Arm, normal saline followed by metoprolol

50ml 0.9% NaCl will be administered over a time interval of 15 minutes. Intravenous metoprolol 5 mg will be immediately administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of saline will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity.

The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.

其他名称:
  • 对照(50ml 0.9% NaCl)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Ventricular rate control
大体时间:Within the first 2 hours of intravenous magnesium administration

Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of < 120 beats per minute.

Within the first 2 hours of intravenous magnesium administration

次要结果测量

结果测量
措施说明
大体时间
Mean change in heart rate
大体时间:up to 24 hours after magnesium infusion

Mean change in heart rate after the administration of magnesium sulfate

up to 24 hours after magnesium infusion
Incidence of hypotension
大体时间:At 1 and 2 hours after magnesium administration

Systolic blood pressure < 90 or MAP < 65

At 1 and 2 hours after magnesium administration
Incidence of bradycardia
大体时间:At 1 and 2 hours after magnesium administration

Heart rate < 60 beats per minute

At 1 and 2 hours after magnesium administration
Mean time to achieve goal heart rate
大体时间:at 2 hours

Mean time to achieve goal heart rate at 2 hours

at 2 hours
Rate of conversion
大体时间:2 hours after administration of magnesium

Rate of conversion to normal sinus rhythm

2 hours after administration of magnesium
Clinical need for rescue medication administration
大体时间:2 hours from metoprolol administration

Dose of rescue medications given (magnesium and metoprolol)

2 hours from metoprolol administration
Mean change in heart rhythm
大体时间:up to 24 hours after magnesium infusion

Mean change in heart rhythm after the administration of magnesium sulfate

up to 24 hours after magnesium infusion
Clinical need for rescue medication administration
大体时间:2 hours from metoprolol administration

Route of administration (IV or PO) for rescue medications (magnesium and metoprolol), if administered.

2 hours from metoprolol administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Marc McDowell, PharmD、Advocate Christ Medical Center Emergency Department

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年11月10日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年5月21日

首先提交符合 QC 标准的

2026年6月2日

首次发布 (实际的)

2026年6月8日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅